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ABSTRACT
Objective: To investigate whether the location and extent of the CT hyperdense artery sign (HAS)
at presentation affects response to IV alteplase in the randomized controlled Third International
Stroke Trial (IST-3).
Methods: All prerandomization and follow-up (24–48 hours) CT brain scans in IST-3 were
assessed for HAS presence, location, and extent by masked raters. We assessed whether HAS
grew, persisted, shrank, or disappeared at follow-up, the association with 6-month functional
outcome, and effect of alteplase. IST-3 is registered (ISRCTN25765518).
Results: HAS presence (vs absence) independently predicted poor 6-month outcome (increased
Oxford Handicap Scale [OHS]) on adjusted ordinal regression analysis (odds ratio [OR] 0.66,
p , 0.001). Outcome was worse in patients with more (vs less) extensive HAS (OR 0.61, p 5
0.027) but not in proximal (vs distal) HAS (p 5 0.420). Increasing age was associated with more
HAS growth at follow-up (OR 1.01, p 5 0.013). Treatment with alteplase increased HAS shrink-
age/disappearance at follow-up (OR 0.77, p5 0.006). There was no significant difference in HAS
shrinkage with alteplase in proximal (vs distal) or more (vs less) extensive HAS (p5 0.516 and p5
0.580, respectively). There was no interaction between presence vs absence of HAS and benefit
of alteplase on 6-month OHS (p 5 0.167).
Conclusions: IV alteplase promotes measurable reduction in HAS regardless of HAS location or
extent. Alteplase increased independence at 6 months in patients with and without HAS.
Classification of evidence: This study provides Class I evidence that for patients within 6 hours of
ischemic stroke with a CT hyperdense artery sign, IV alteplase reduced intra-arterial hyperdense
thrombus. Neurology® 2016;86:118–125
GLOSSARY
ACA 5 anterior cerebral artery; CI 5 confidence interval; HAS 5 hyperdense artery sign; HU 5 Hounsfield units; ICA 5
internal carotid artery; IST-3 5 Third International Stroke Trial; MCA 5 middle cerebral artery; NIHSS 5 NIH Stroke Scale;
OHS5Oxford Handicap Scale;OR5 odds ratio; PCA5 posterior cerebral artery; SIRS5 Systematic Image Review System.
Arterial hyperattenuation on noncontrast CT, the hyperdense artery sign (HAS), is a consis-
tently recognized CT sign of acute ischemic stroke.1 HAS is highly specific and moderately
sensitive for intracranial arterial obstruction by thrombus.2 HAS is associated with increased
stroke severity at presentation and worse long-term outcomes.3–5 There are, however, limited
data on how the location, extent, or persistence of HAS relates to functional outcome following
stroke, and importantly whether patients with (vs without) HAS benefit differently from IV
thrombolysis with alteplase.6–9
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The Third International Stroke Trial (IST-3)
was a large (n 5 3,035), multicenter, random-
ized controlled trial testing IV alteplase given
within 6 hours of ischemic stroke.10 A central
masked panel assessed prerandomization and
follow-up CT for the presence of HAS.
We analyzed IST-3 imaging data to investi-
gate whether, in this large, prospectively studied
group of patients, the presence, location, and
extent of HAS was associated with response to
IV alteplase assessed as both change in HAS
on short-term follow-up and also its effect on
6-month functional outcome.
METHODS IST-3. IST-3 was an international, multicenter,
prospective, randomized, open, blinded endpoint (PROBE) trial
of IV alteplase in acute ischemic stroke. Enrollment, data collec-
tion, image analysis, and CONSORT compliance have been
described elsewhere.10,11 Briefly, adult patients with acute stroke
of any severity, with no upper age limit, were eligible if IV alteplase
could be started within 6 hours of stroke onset and CT orMRI had
excluded intracranial hemorrhage and any structural stroke mimic.
IST-3 used the uncertainty principle for enrollment, i.e., if the
randomizing clinician believed that alteplase was clearly indicated
or contraindicated, such a patient could not be enrolled; patients
were only enrolled when there was genuine uncertainty over the
benefit of alteplase for that individual.10,11 Stroke severity prior to
randomization was assessed with the NIH Stroke Scale (NIHSS).
After entry of baseline data, patients were randomized to receive IV
alteplase (0.9 mg/kg) or control. Results were analyzed on an
intention-to-treat basis. Patients were followed by postal
questionnaire or masked telephone interview at 6 months and
functional status assessed with the Oxford Handicap Scale (OHS).
Standard protocol approvals, registrations, and patient
consents. Ethical approval for IST-3 was granted by the Scotland
A research ethics committee and by local ethics committees.
Informed consent was obtained for all patients. IST-3 is
registered with Current Controlled Trials, ISRCTN25765518.
Imaging protocol. The IST-3 imaging protocol has been
described previously.10,12 Briefly, CT scans were required to cover
the brain from foramen magnum to vertex, with maximum slice
thickness 4–5 mm through the posterior fossa and 8–10 mm for
the cerebral hemispheres, with no slice gap. Thinner slices were also
accepted. Scans were windowed on 80 Hounsfield units (HU)
width and center level of 35–40 HU. Follow-up brain imaging
(CT or MRI) was also required, to the same protocol, for all
patients, between 24 and 48 hours after stroke onset. All imaging
was reviewed centrally for quality control and validation.
Image analysis. A centralized panel of neuroradiologists and
neurologists experienced in reviewing stroke imaging analyzed all
imaging with an online assessment tool, the Systematic Image
Review System (SIRS), recording assessments on a validated
structured pro forma1,13 available at www.sbirc.ed.ac.uk/research/
imageanalysis.html, accessed November 23, 2015. Assessors were
masked to all other imaging and clinical data. HAS presence was
determined visually (i.e., the reader decided if a vessel appeared
hyperdense; no objective HU measurements were made). Where
present, the location and extent of HAS was recorded by selecting
the 3 largest vessels affected from the following options: internal
carotid artery (ICA), middle cerebral artery (MCA) mainstem,
sylvian branches of MCA, anterior cerebral artery (ACA), posterior
cerebral artery (PCA), vertebral artery, basilar artery. A subgroup of
scans (n5 272) underwent a second independent read as part of the
IST-3 angiography and perfusion imaging substudy.14 Secondary
reads were performed by a different panel of assessors (see
coinvestigator list on the Neurology® Web site at Neurology.org)
using SIRS as described above. Scans that were read twice were
used to test interrater reliability of HAS assessment.
Data analysis. These analyses are restricted to patients with a
noncontrast CT obtained prerandomization. The location of
HAS was classified as proximal (ICA, MCA mainstem, vertebral
or basilar arteries) or distal (ACA, PCA, or sylvian branches of the
MCA). HAS extent was classified by the number of contiguous
named vessels involved (0, 1, 2, or 3 as per the predefined options).
We compared prerandomization and follow-up scans in all patients
who had noncontrast CT performed at both times and calculated
the change in HAS segment number from a minimum of 23 to
a maximum of 13 (negative numbers indicate shrinkage and
positive numbers indicate growth of HAS).
Statistics. We used univariate and multivariate tests to examine
differences between all IST-3 patients and the subset who were HAS-
positive prerandomization, between the treatment and control
groups with HAS, and for associations among the presence, extent,
location, and persistence of HAS, baseline clinical features, and
effect of alteplase.
For univariate analysis of parametric data, we used t tests to
compare ratios and means; for nonparametric data, we used Mann-
Whitney U tests. We calculated x2 statistics for dichotomous data.
We used Krippendorffa (K-a) to test interrater reliability. K-a results
range from21.0 to11.0 where11.0 equates to perfect agreement,
0.0 means no agreement, and 21.0 implies perfect disagreement.15
We used multivariate ordinal regression to calculate common
odds ratios (ORs) with 6-month OHS and change in HAS segment
number as dependent variables.16 We tested the effect of HAS pres-
ence, extent, and location on outcome in separate models. Consis-
tent with the main IST-3 analyses,10,17 multivariate models were
adjusted for the effect of patient age, NIHSS, and time from stroke
onset to prerandomization scan since these variables predicted out-
come in the main trial.10 To reduce confounding between HAS
extent and location on outcome, the effect of location was assessed
only among those with HAS in a single arterial segment. To stabilize
ordinal regression estimates, we used the same approach as the
original IST-3 analysis of functional outcome, where the more
severe grades of OHS (4–6) were grouped as one, leaving 5 ordinal
analysis groups.17 Similarly, the variable time from stroke onset to
prerandomization scan was grouped into 6 1-hour windows (0–6
hours), the variable time from prerandomization scan to follow-up
scan was grouped into 5 12-hour windows (#12, 13–24, 25–36,
37–48, and .48 hours) and the variable change in HAS segment
number was grouped into 3 outcomes (fewer segments5 shrinkage,
no change, more segments 5 growth).
We performed tests of interaction (using ComprehensiveMeta-
Analysis software; Biostat, Englewood, NJ) to compare ORs for the
effect of IV alteplase on change in HAS extent in distal vs proximal
HAS and in 1 segment vs .1 segment HAS and to compare the
effect of alteplase on outcome in those with vs those without HAS.
All other analyses were performed with IBM SPSS statistics
software, version 20.0 (IBM Corporation, Armonk, NY). We
considered p , 0.05 significant.
Primary research question. To assess the response of HAS to
IV alteplase and to determine if the presence, location, extent, or
persistence of HAS modified the effect of alteplase on outcome.
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Classification of evidence. This study provides Class I evi-
dence that IV alteplase (0.9 mg/kg) given within 6 hours of ische-
mic stroke onset accelerates shrinkage of HAS at follow-up 24–48
hours later.
RESULTS Demographics and clinical and outcome
data. Most IST-3 patients had noncontrast CT
performed both prerandomization (2,961/3,035,
97.6%) and at follow-up (2,779/3,035, 91.6%) 24–
48 hours later. MRI was the imaging method in 56
and 151 patients, respectively. Prerandomization or
follow-up CT scans were not available for central
review in 18 (0.6%) and 105 cases (3.5%),
respectively. Thus, the total number of patients
with centrally reviewed CT both prerandomization
and at follow-up was 2,731 (90.0% of 3,035). HAS
data were missing for one follow-up CT (poor
quality). There were no significant differences in the
demographic and clinical data for the 2,961 patients
with centrally reviewed prerandomization CT, nor for
the 2,731 patients who also had follow-up CT when
both groups were compared with 3,035 patients in
the full IST-3 trial (data not shown).
The results of interrater reliability are as follows:
for HAS identification, K-a 5 0.40; for assessment
of the largest artery involved, K-a 5 0.46; and for
assessment of HAS extent, K-a 5 0.39.
Of 2,961 patients with prerandomization CT,
716 (24.2%) demonstrated HAS. On univariate anal-
ysis, patients with baseline HAS were younger and
had a more severe stroke and worse 6-month out-
comes than those without HAS (table 1). Among
patients with HAS, those allocated control had an
increased median time between prerandomization
and follow-up scans compared with patients allocated
alteplase. None of the other demographic or clinical
measures in patients with HAS were significantly
different between alteplase and control groups (table
e-1).
For the multivariable ordinal analysis testing pre-
randomization variables associated with 6-month out-
come in the whole group (OHS as dependent
variable, n 5 2,961), alteplase treatment allocation
independently predicted a better outcome (lower
OHS); OR 1.29, 95% confidence interval (CI)
1.12–1.50, p5 0.001. In the same analysis, the pres-
ence vs absence of HAS independently predicted a
worse outcome (higher OHS, figure e-1); OR 0.66,
95% CI 0.55–0.80, p , 0.001. These results are
adjusted for age, NIHSS, and time from stroke onset
to scan (table 2 and figure 1).
Location, extent, and persistence of HAS. For 2,731 pa-
tients with CT performed prerandomization and at
follow-up, HAS was identified on 674 (24.7% of
2,731) prerandomization and 520 (19.0%) follow-up
scans. In 870 cases (31.9%), HAS was evident on
at least one scan. On univariate analyses, 6-month
outcome was worse if HAS was found only in
proximal rather than only in distal vessels, if HAS
was more vs less extensive, if HAS showed growth
rather than shrinkage between scans, if HAS
persisted at follow-up rather than disappeared, and
if a new HAS developed between scans (table e-2).
For multivariate analyses testing the effect of HAS
characteristics on outcome (OHS as dependent variable)
among patients with HAS in the whole group (n 5
716), HAS extent (1, 2, or 3 segments) independently
predicted a worse outcome (higher OHS); OR 0.61,
95% CI 0.39–0.94, p 5 0.027. In patients with HAS
in only 1 arterial segment (n 5 589), HAS location
(proximal vs distal) was not independently associated
with outcome, OR 1.17, 95% CI 0.80–1.71, p 5
0.420. These analyses are adjusted for age, NIHSS, time
Table 1 Demographic and clinical data of IST-3 patients with and without a HAS on prerandomization CT
All patients (n 5 2,961)
Comparison of those with and without HAS
HAS (n 5 716) (24.2%) No HAS (n 5 2,245) (75.8%)
p Value for
difference
Age, y, median (IQR) 81 (72–86) 80 (70–85) 81 (72–86) 0.003
Male sex, n (%) 1,427 (48.2) 356 (49.7) 1,071 (47.7) 0.348
Stroke onset to prerandomization scan, min, mean (SD) 163 (73) 159 (71) 164 (73) 0.082
Time to imaging follow-up, h, median (IQR) 26 (24–36) 26 (24–38) 26 (24–35) 0.801
Baseline NIHSS, median (IQR) 11 (6–18) 16 (10–20) 9 (6–16) ,0.001
OHS at 6 months, median (IQR) 4 (2–6) 5 (3–6) 3 (1–5) ,0.001
Death by 6 months, n (%) 797 (26.9) 263 (36.7) 534 (23.8) ,0.001
Treated with alteplase, n (%) 1,484 (50.1) 368 (51.4) 1,116 (49.7) 0.432
Abbreviations: HAS5 hyperdense artery sign; IQR5 interquartile range; IST-35 Third International Stroke Trial; NIHSS5 NIH Stroke Scale; OHS5Oxford
Handicap Scale.
Analysis restricted to patients with prerandomization CT imaging only (n 5 2,961).
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from stroke onset to scan, and treatment allocation
(table 2).
Effect of alteplase on HAS. There were univariate asso-
ciations between alteplase treatment and an increased
likelihood of both HAS shrinkage and HAS disappear-
ance (222/4405 50.5% vs 166/4295 38.7% shrank,
x25 12.6, p5 0.002, and 198/3505 56.6% vs 151/
323 5 46.7% disappeared, x2 5 6.5, p 5 0.011,
respectively). In patients treated with alteplase, distal
vs proximal HAS (65/86 5 75.6% vs 105/198 5
53.0%, respectively, x25 12.7, p, 0.001) and single
segment vs multisegment HAS (170/2845 59.9% vs
28/66 5 42.4%, respectively, x2 5 6.6, p 5 0.010)
were more likely to have disappeared at follow-up.
Fewer patients who received alteplase had developed
a new HAS in the interim between pre-randomization
and follow-up CT, although the difference was not
Table 2 Multivariable analyses testing the importance of HAS presence, extent, and location on 6-month outcome
Raw data Odds ratio 95% CI p Value
Presence of HAS (n 5 2,961)
Age, y 81 (72–86) 0.96 0.96–0.97 ,0.001
NIHSS 11 (6–18) 0.84 0.83–0.85 ,0.001
Stroke onset to prerandomization scan, h 3 (2–4) 1.07 1.01–1.14 0.018
HAS present n 5 716 0.66 0.55–0.80 ,0.001
Treated with alteplase n 5 1484 1.29 1.12–1.50 0.001
Extent of HAS (n 5 716)
Age, y 80 (70–85) 0.95 0.94–0.96 ,0.001
NIHSS 16 (10–20) 0.84 0.82–0.87 ,0.001
Stroke onset to prerandomization scan, h 3 (2–4) 1.06 0.92–1.22 0.412
HAS extent (1–3 segments) 1 (1–1) 0.61 0.39–0.94 0.027
Treated with alteplase n 5 368 1.06 0.76–1.48 0.714
Location of HAS (n 5 589)
Age, y 81 (71–85) 0.95 0.94–0.97 ,0.001
NIHSS 15 (10–20) 0.84 0.81–0.87 ,0.001
Stroke onset to prerandomization scan, h 3 (2–4) 1.03 0.89–1.20 0.681
HAS in distal location (rather than proximal) n 5 182 1.17 0.80–1.71 0.420
Treated with alteplase n 5 301 1.15 0.81–1.64 0.442
Abbreviations: CI 5 confidence interval; HAS 5 hyperdense artery sign; NIHSS 5 NIH Stroke Scale.
Ordinal regression analyses with Oxford Handicap Scale as the dependent variable for each. Presence of HAS 5 all Third International Stroke Trial patients
with prerandomization CT. Extent of HAS5 includes only patients with HAS on prerandomization CT. Location of HAS5 includes only patients with HAS in
a single arterial segment on prerandomization CT. Raw data provided as median (interquartile range) unless otherwise stated. Odds ratio ,1 indicates
worse outcome.
Figure 1 Separate ordinal regression analyses show odds ratios for the effect of alteplase treatment on
6-month functional outcome in the full group (n 5 2,961) and in the subgroups with and without
a hyperdense artery sign (HAS) on prerandomization CT
Odds ratio .1 (right of line) indicates better outcome (lower 6-month Oxford Handicap Scale). Results for the HAS and no
HAS groups are adjusted for the effect of age, time from stroke onset to scan (hours), and NIH Stroke Scale (NIHSS) score.
Results for the full group are adjusted for the effect of age, time from stroke onset to scan (hours), NIHSS, and presence/
absence of HAS.
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significant (90/957 5 9.4% vs 106/904 5 11.8%,
x2 5 2.2, p 5 0.143).
For multivariate analyses, testing factors associated
with change in HAS segment number (dependent
variable), alteplase treatment was an independent pre-
dictor of HAS shrinkage at follow-up (OR 0.77, 95%
CI 0.65–0.93, p 5 0.006), while HAS growth was
more likely in older patients (OR 1.01, 1.00–1.02,
p 5 0.013) (table 3). Both proximal and distal HAS
were equally likely to shrink following alteplase treat-
ment (OR 0.66, 95% CI 0.45–0.98, and OR 0.51,
95% CI 0.26–1.00, respectively), with no evidence of
an interaction between HAS location and alteplase
effect (p 5 0.516) (figure 2). HAS affecting a single
arterial segment prerandomization was more likely to
shrink following alteplase treatment (OR 0.60, 0.43–
0.85), but alteplase was not an independent predictor
of HAS shrinkage if more than 1 segment was affected
prerandomization (OR 0.78, 95% CI 0.33–1.86).
Nevertheless, there was no evidence of an interaction
between HAS extent and alteplase effect (p 5 0.580)
(figure 2). These results are adjusted for patient age,
time (between prerandomization and follow-up
scans), and stroke severity.
Effect of alteplase on patient outcome in those with HAS.
Results of multivariate analysis of alteplase effect on
outcome (OHS as dependent variable) for the sub-
groups with (OR 1.05, 0.75–1.45) and without
(OR 1.36, 1.16–1.60) HAS on prerandomization
CT are shown in figure 1. There was no evidence
of an interaction with the presence vs absence of
HAS (p 5 0.167).
DISCUSSION In this analysis of IST-3, we show that
IV alteplase both reduces the persistence (more likely
to shrink, or disappear) and limits the formation (less
likely to grow) of HAS compared to patients allocated
control. We found that alteplase increases HAS
shrinkage/disappearance independent of age, baseline
stroke severity, and time between prerandomization
and follow-up scans. While HAS disappearance
following treatment with alteplase was more common
for small or distal vs large or proximal HAS on
univariate analysis, the alteplase effect on HAS
reduction/shrinkage was similar across all subgroups
on multivariate regression analysis. We found no
difference in the likelihood of HAS shrinkage for
proximal vs distal HAS or for single segment vs
multisegment HAS, i.e., alteplase reduces all HAS but
is less able to remove the larger volume completely,
usually more proximally sited HAS. We should note
that alteplase treatment did not independently predict
reduction of multisegment HAS but there was a trend
toward such an association and this analysis is
underpowered. Our findings are particularly relevant
given recent evidence supporting the use of
endovascular clot retrieval in ischemic stroke18–20 since
Table 3 Factors associated with change in extent of HAS from
prerandomization to follow-up scan (n 5 2,730a)
Raw data Odds ratio 95% CI p Value
Age, y 81 (72–86) 1.01 1.00–1.02 0.013
Baseline NIHSS 11 (6–18) 1.00 0.98–1.01 0.475
Prerandomization scan to follow-up
scan, h
26 (24–36) 0.91 0.82–1.00 0.059
Treated with alteplase n 5 1397 0.77 0.65–0.93 0.006
Abbreviations: CI 5 confidence interval; HAS 5 hyperdense artery sign; NIHSS 5 NIH
Stroke Scale.
Ordinal regression analysis with change in HAS segment number (shrinkage, no change,
growth) as the dependent variable. Raw data provided as median (interquartile range) unless
otherwise stated. Time between scans was divided into 5 groups (#12, 13–24, 25–36,
37–48, and .48 hours). Odds ratio ,1 indicates HAS shrinkage, .1 indicates HAS growth.
aHAS data were missing for one follow-up CT (poor quality scan).
Figure 2 Ordinal regression analyses for the effect of treatment on change in HAS extent from prerandomization to follow-up scan
Ordinal regression analyses with change in HAS segment number (shrinkage, no change, growth) as the dependent variable assessing the importance of
prerandomization HAS location (proximal 5 internal carotid artery, middle cerebral artery mainstem, vertebral or basilar arteries; distal 5 anterior or
posterior cerebral arteries or sylvian branches of the middle cerebral artery) and HAS extent on the effect of alteplase. *Location analysis does not include
patients with HAS in both proximal and distal arteries. Odds ratio ,1 (left of line) indicates HAS shrinkage, .1 (right of line) indicates HAS growth. Results
are adjusted for the effect of age, time from stroke onset to scan (hours), and NIH Stroke Scale score.
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not all patients will have the opportunity to receive, or
be eligible for, such treatment. In addition, we and
others7,8 have shown improved patient outcome where
HAS shrinks or disappears with IV alteplase.
Conversely, increasing patient age was an independent
predictor of HAS growth, which may help to explain
poorer stroke outcomes in the elderly.
Our work demonstrates a novel association
between IV thrombolysis and measurable growth/
shrinkage of HAS using randomized controlled trial
data. We found no evidence that presence or absence
of HAS materially altered the benefit of alteplase (the
favorable shift in 6-month OHS). While the ordinal
regression results for the HAS group alone are nonsig-
nificant, this subgroup is underpowered and should
be interpreted with caution. The appropriate inter-
pretation is that there is no evidence of a difference
in treatment effect between those with and without
HAS at baseline, not that alteplase has no effect in
those with HAS. To understand the apparent benefit
of alteplase in patients without HAS, the presence of
undetected thrombosis may be an answer; a recent
report demonstrated benefit from thrombolysis for
patients without apparent arterial obstruction on
angiography.21
In IST-3, HAS was present in approximately 25%
of patients within 6 hours of acute stroke. This is con-
sistent with other published large series using similar
scanning protocols22,23 although HAS prevalence
rates of 47%–59% were reported in smaller stud-
ies.24,25 We confirmed that patients with HAS have
more severe strokes and worse 6-month outcomes
than patients without HAS. The effect of HAS pres-
ence on outcome is independent of age, time from
stroke onset, stroke severity, and treatment with IV
alteplase, i.e., patients with and without HAS both
benefit from alteplase. Other authors have demon-
strated that HAS independently predicts out-
come,8,26,27 but our work also demonstrates that
more extensive HAS independently predicts worse
outcome among patients with the sign. We did not
demonstrate an independent association between
HAS location and outcome despite highly significant
univariate results as demonstrated elsewhere9; how-
ever, our multivariate analysis of outcome by HAS
location is limited by the exclusion of those HAS
affecting more than one arterial segment and may
be underpowered.
Our study has limitations. First, some CT scans
were not thin-section but prevalence rates for HAS
are greater with thin-slice protocols.2 Our preran-
domization HAS prevalence may therefore be an
underestimate. Second, our estimates of interrater
reliability ranged from K-a 0.39 to 0.46. Prior studies
have reported kappa (numerically equivalent to K-a)
for the identification of HAS in the 0.36–0.91 range,
but these studies rarely involved more than 2 readers,
whereas our panel consisted of 10 individuals masked
to correlative clinical and imaging data.2,28 Third, we
did not define HAS based on HU measurements.
Our central image analysis was performed qualita-
tively to reflect acute stroke care. A recent cohort
study demonstrated that following IV alteplase, ische-
mic stroke patients with persistent arterial occlusion
had lower mean density of thrombus compared to
those who achieved recanalization.29 We are assessing
the effect of thrombus density on outcome in IST-3
in separate analyses. Fourth, we estimated hyperden-
sity extent based on the number of arterial segments
affected. A volumetric measurement may have pro-
vided a more accurate assessment of changes in HAS
volume. However, it remains unclear if HAS volume
can be measured reliably. Our method of assessing
thrombus extent is relevant to daily practice. Fifth,
we used HAS disappearance as a surrogate indicator
of arterial recanalization in the absence of angio-
graphic data for all patients. We are analyzing avail-
able angiography data from IST-3 in a separate
analysis. Sixth, multivariate models were adjusted
only for variables that were associated with outcome
in the main IST-3 analysis10 and for the variable time
from stroke onset to scan since this latter variable
would likely affect the appearance of HAS. Seventh,
the limitations of the full IST-3 trial have been
previously discussed10 including use of the uncer-
tainty principle for enrolment and the potential
introduction of bias through the adoption of an
open design. Finally, even with 3,000 patients,
IST-3 has insufficient power to reliably explore
interactions between HAS and the effect of alte-
plase, but we found little evidence that patients
with HAS responded differently to alteplase than
those without HAS.
We confirmed, using data from a large randomized
controlled trial, associations between the presence and
extent of HAS and poor 6-month outcomes. We show
clearly that alteplase accelerates shrinkage of HAS,
regardless of HAS location and extent. Furthermore,
we found no evidence that the improvement in func-
tional outcome following alteplase was materially dif-
ferent in the presence or absence of HAS. Therefore,
while HAS is useful to support a diagnosis of acute
ischemic stroke and helps predict outcome, our data
suggest that the presence or absence of the sign should
not preclude the use of IV alteplase where clinically
appropriate.
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Anti-GAD antibody syndrome with concomitant cerebellar
ataxia, stiff person syndrome, and limbic encephalitis (see the
December 2015 issue of Neurology® Clinical Practice)
This podcast begins and closes with Dr. Robert Gross, Editor-in-
Chief, briefly discussing highlighted articles from the January 12,
2016, issue of Neurology. In the second segment, Dr. Alex Menze
talks with Dr. Sara Schaefer about her Neurology: Clinical Practice
paper on anti-GAD antibody syndrome with concomitant cere-
bellar ataxia, stiff person syndrome, and limbic encephalitis.
Dr. Ted Burns interviews Cathy Rydell about current exciting
projects happening at the AAN in our “What’s Trending” fea-
ture of the week. In the next part of the podcast, Dr. Prachi Mehndiratta focuses her interview with
Dr. Max Wintermark on the topic of imaging modalities used as selection criteria in endovascular
stroke therapy.
Disclosures can be found at Neurology.org.
At Neurology.org, click on “RSS” in the Neurology Podcast box to listen to the most recent
podcast and subscribe to the RSS feed.
No CME will be offered this week: Interviews based on articles from Neurology: Clinical Practice,
Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation are excluded from
the CME program.
Neurology 86 January 12, 2016 125
ª 2015 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
DOI 10.1212/WNL.0000000000002236
2016;86;118-125 Published Online before print December 9, 2015Neurology 
Grant Mair, Rüdiger von Kummer, Zoe Morris, et al. 
Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke
This information is current as of December 9, 2015
Services
Updated Information &
 http://www.neurology.org/content/86/2/118.full.html
including high resolution figures, can be found at:
Supplementary Material
 002236.DC2.html
http://www.neurology.org/content/suppl/2015/12/09/WNL.0000000000
 002236.DC1.html
http://www.neurology.org/content/suppl/2015/12/09/WNL.0000000000
Supplementary material can be found at: 
References
 http://www.neurology.org/content/86/2/118.full.html##ref-list-1
This article cites 25 articles, 11 of which you can access for free at: 
Subspecialty Collections
 http://www.neurology.org//cgi/collection/infarction
Infarction
 http://www.neurology.org//cgi/collection/ct
CT
 ontrolled_consort_agreement
http://www.neurology.org//cgi/collection/clinical_trials_randomized_c
Clinical trials Randomized controlled (CONSORT agreement)
 http://www.neurology.org//cgi/collection/class_1
Class I
following collection(s): 
This article, along with others on similar topics, appears in the
  
Permissions & Licensing
 http://www.neurology.org/misc/about.xhtml#permissions
its entirety can be found online at:
Information about reproducing this article in parts (figures,tables) or in
  
Reprints
 http://www.neurology.org/misc/addir.xhtml#reprintsus
Information about ordering reprints can be found online:
rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.
1951, it is now a weekly with 48 issues per year. Copyright © 2015 American Academy of Neurology. All 
® is the official journal of the American Academy of Neurology. Published continuously sinceNeurology 
